On 28 January 2015, we announced that our major three-part transaction with Novartis has completed.
As a result, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and divested our marketed Oncology business to Novartis.
